



From Tradition to Therapy: Varieties and Uses of Sareyaka (*Barleria Prionitis* L.) in Ayurveda

*Dr. Man Singh Meena, Dr Jishnu T. K¹, Dr. Rajesh Sharma²

*¹PG Scholar (Ayu). Dravyaguna Department, A&U Tibbia College & Hospital, Karol Bagh New Delhi

² Professor (Ayu), H.O.D, Dravyaguna Department, A&U Tibbia College & Hospital Karol Bagh Delhi

ABSTRACT

Barleria prionitis L., a prominent herb in the Acanthaceae family, holds a distinguished position in traditional medical systems, particularly Ayurveda, where it is revered under names such as Sareyaka, Kurantaka, and Vajradanti. Native to tropical regions of Asia and Africa, this spiny shrub has a long history of use for a wide spectrum of ailments, including dental diseases, inflammatory conditions, skin disorders, and fevers. This comprehensive review bridges the gap between its classical Ayurvedic applications and contemporary scientific validation. It delves into the plant's detailed botanical profile, including its taxonomical classification, morphological characteristics, and the biogeographical distribution of its distinct subspecies, which has significant implications for phytochemical consistency and therapeutic efficacy. The report systematically outlines the plant's Ayurvedic pharmacology (*Dravyaguna*), analyzing how its properties—*Rasa* (taste), *Guna* (quality), *Virya* (potency), and *Vipaka* (post-digestive effect)—underpin its traditional therapeutic actions, especially in balancing *Vata* and *Kapha doshas*. A thorough examination of the plant's rich phytochemical landscape reveals a plethora of bioactive compounds, with iridoid glycosides (e.g., barlerin, acetylbarlerin, shanzhiside methyl ester), flavonoids, and phenylethanoid glycosides emerging as key therapeutic agents. Extensive pharmacological studies have substantiated many of its traditional uses, demonstrating potent anti-inflammatory, anti-arthritic, antimicrobial, antioxidant, hepatoprotective, nephroprotective, and analgesic activities. The congruence between the etymology of its Sanskrit names, such as Vajradanti ("diamond-strong teeth"), and its scientifically proven anti-dental properties exemplifies the profound observational basis of Ayurvedic medicine. This review synthesizes this evidence, discusses aspects of quality control and safety, and proposes future research directions, positioning *B. prionitis* as a promising candidate for the development of modern phytopharmaceuticals and as a model for the scientific exploration of traditional herbal remedies.

1. Introduction

For millennia, natural products have formed the bedrock of human healthcare systems. Among the vast botanical pharmacopoeia of Ayurveda, the ancient Indian system of medicine, *Barleria prionitis* L. occupies a place of considerable importance. Known classically by a host of evocative Sanskrit names including Sareyaka, Kurantaka, Sahachara, and most popularly, Vajradanti, this resilient, spiny shrub is a cornerstone of traditional healing practices not only in the Indian subcontinent but also across tropical Africa and Asia.¹ Its widespread use in folk medicine for treating an array of conditions—from toothaches and joint pain to fevers and skin infections—has cemented its status as a versatile and indispensable therapeutic agent.²

The journey of *B. prionitis* from a traditional remedy to a subject of modern scientific inquiry forms the central theme of this review. This transition represents a powerful example of how ancient wisdom can guide contemporary pharmacological research. The classical descriptions of the plant's properties and uses, codified in Ayurvedic texts, have provided a roadmap for scientists seeking to uncover its chemical constituents and validate its therapeutic potential through rigorous experimental models. The remarkable alignment between the plant's traditional applications and its scientifically demonstrated biological activities offers a compelling narrative of validation, bridging the empirical knowledge of the past with the evidence-based standards of the present.²

This report aims to provide a comprehensive, multi-disciplinary synthesis of the current knowledge on *Barleria prionitis*. It will navigate the full spectrum of its identity, beginning with its botanical and taxonomical profile to establish its precise characterization. It will then delve into its classical role within the Ayurvedic pharmacopoeia, exploring its properties (*Dravyaguna*), its mention in seminal texts, and its inclusion in key formulations. Following this, the review will catalogue its extensive ethnomedicinal applications, which serve as the foundation for modern investigation. The subsequent sections will focus on its rich phytochemical landscape and the wealth of pharmacological studies that have validated its anti-inflammatory, antimicrobial, antioxidant, and analgesic effects, among others. By examining the plant through these integrated lenses, this report seeks to construct a holistic understanding of *B. prionitis*, tracing its path from a revered traditional herb to a promising source of future therapeutic agents.

2. Botanical and Taxonomical Profile

A precise understanding of a medicinal plant's botanical identity is the sine qua non for any credible pharmacological or clinical research. It ensures reproducibility, prevents adulteration, and allows for the accurate interpretation of historical and ethnomedicinal literature.

2.1. Taxonomy and Nomenclature

Barleria prionitis L. belongs to the family Acanthaceae, a large family of dicotyledonous flowering plants.¹ Its detailed taxonomic classification is as follows:

- **Kingdom:** Plantae
- **Phylum:** Spermatophyta
- **Class:** Dicotyledonae
- **Order:** Scrophulariales
- **Family:** Acanthaceae
- **Genus:** *Barleria*
- **Species:** *Barleria prionitis* L.¹

The genus *Barleria* is a large, polymorphic, and widespread group, comprising approximately 300 species with its greatest diversity centered in tropical East Africa.¹ The genus is readily distinguished from others in the Acanthaceae family by a combination of three key features: a four-merous calyx with two large outer sepals and two smaller inner ones; globose, honey-combed pollen; and a predominance of double cystoliths (calcium oxalate crystals) in its epidermal cells.¹ To avoid confusion in reviewing historical and regional literature, it is important to note its botanical synonyms, which include *Barleria hystrix* L., *Barleria quadrispinosa* Stokes, and *Prionitis hystrix* (L.) Miq.⁷

2.2. Varieties and Subspecies

The species *B. prionitis* is not monolithic; Carl Linnaeus first described the plant in 1753, and in 1983, three distinct subspecies were formally recognized, each with a specific native geographical range⁷:

- ***B. prionitis* subsp. *appressa*** (Forssk.) Brummitt & J.R.I.Wood: Native to the Arabian Peninsula, specifically Saudi Arabia and Yemen.
- ***B. prionitis* subsp. *induta*** (C.B.Clarke) Brummitt & J.R.I.Wood: Native to northeastern Africa, found in Ethiopia and Eritrea.
- ***B. prionitis* subsp. *pubiflora*** (Benth. ex Hohen.) Brummitt & J.R.I.Wood: Native to the Indian subcontinent, with a more restricted range in western India (coastal areas, Himalayan foothills, eastern Punjab) and southeast Pakistan. This subspecies is distinguished from the nominate subspecies by having a larger corolla (4.5–7 cm), longer anthers (≥5 mm), and larger leaves.⁷

The existence of these geographically isolated subspecies has profound implications for the study and application of this medicinal plant. It is well-established in pharmacognosy that environmental factors such as soil composition, climate, and altitude significantly influence a plant's secondary metabolite production, leading to the development of different chemotypes. Therefore, it is highly probable that *B. p. subsp. appressa*, *B. p. subsp. induta*, and *B. p. subsp. pubiflora* possess distinct phytochemical profiles. This potential variation could account for regional differences in traditional uses and poses a significant challenge for the global standardization of herbal medicines derived from *B. prionitis*. A therapeutic formulation developed and tested in India using the local *subsp. pubiflora* may not yield the same clinical outcomes if manufactured elsewhere using a different subspecies. This underscores a critical need for future research to conduct comparative phytochemical and pharmacological analyses of these subspecies to validate this hypothesis and inform global quality control standards.

2.3. Morphological and Anatomical Description

Macroscopic Features: *B. prionitis* is a small, erect, much-branched spiny shrub, typically growing to a height of 0.6–1.8 meters.¹ Its stems are terete, smooth, and glabrous, becoming light tan or grey with age.⁹ The most striking morphological feature, which gives the plant its common name "Porcupine Flower," is the presence of sharp, pale-colored spines, typically in groups of three to five, located in the axils of the lower leaves.¹ The leaves are simple, oppositely arranged, elliptic to ovate in shape, and measure 4–13 cm in length and 1.5–5.5 cm in width, with an acute apex that often ends in a short spine.¹ The flowers are a vibrant golden-yellow to orange, tubular in shape (3–4 cm long), and are clustered in the axils of the upper leaves or bracts. The fruit is a beaked, ovoid capsule about 1.3–2 cm long, which contains two flat, hairy seeds.¹

Microscopic and Anatomical Features: Pharmacognostic evaluation reveals several microscopic characteristics that are vital for authenticating the crude drug and distinguishing it from potential adulterants. The leaf is amphistomatous (stomata on both surfaces) with predominantly diacytic stomata.¹⁰ A key diagnostic feature is the presence of cystoliths—deposits of calcium oxalate—which are found as both solitary and paired structures in the epidermal

cells of the stem and leaf.¹ The root and stem exhibit anomalous secondary growth, characterized by the formation of included (or interxylary) phloem, where patches of phloem are embedded within the secondary xylem. The root is diarch and lacks a pith.¹⁰ These detailed anatomical markers provide a scientific basis for quality control and the identification of genuine plant material.

2.4. Geographical Distribution and Ecological Impact

B. prionitis is native to a broad swath of the Old World, including tropical East Africa and tropical and temperate Asia, encompassing the Indian subcontinent, China, and Southeast Asia.¹ In India, its distribution is extensive, recorded across numerous districts in states such as Andhra Pradesh, Karnataka, Kerala, Maharashtra, Odisha, and Tamil Nadu.⁶

Due to its attractive flowers and thorny nature, it has been intentionally introduced worldwide as an ornamental and hedge plant.¹ However, its remarkable adaptability has allowed it to escape cultivation and become naturalized in many new regions. It can thrive in a wide range of climates and soil types, colonizing disturbed sites, open woodlands, roadsides, and overgrazed pastures.¹ This hardiness, combined with its ability to reproduce both by seed and vegetatively through stem fragments, has led to it being classified as an invasive environmental weed in some areas, such as northern Australia, where it can form dense, prickly thickets that displace native vegetation.¹

This ecological success presents a fascinating paradox. The very traits that make *B. prionitis* a problematic invasive species—its resilience, adaptability, and aggressive growth—are the same characteristics that ensure its abundant and reliable availability in its native habitats. For a plant to become a staple in traditional and folk medicine, it must be easily accessible to local communities. The robust nature of *B. prionitis* guarantees this accessibility, forging a direct link between its ecological prowess and its ethnobotanical importance. Its ability to flourish where other plants may not has made it a dependable resource for generations of traditional healers.

Table 1: Vernacular Names of *Barleria prionitis* L. in India

Language	Vernacular Name(s)
Sanskrit	Sareyaka, Pita-Saireyaka, Kurantaka, Sahachaara, Vajradanti
Hindi	Vajradanti
Kannada	Mullu goranti, Haladi goranti
Tamil	Kattukanagambaram, Chemmulli
Marathi	Pivali Koranti
Malayalam	Chemmulli, Majakanakabaram, Shemmuli, Vennkuringiveru

The multiplicity of names across different languages, as shown in Table 1, is a testament to the plant's deep cultural and medicinal integration throughout the Indian subcontinent. This linguistic diversity is crucial for ethnobotanical researchers attempting to trace its use in various regional traditions and historical texts.

3. Sareyaka in the Ayurvedic Pharmacopoeia

The classical texts of Ayurveda provide a sophisticated framework for understanding medicinal plants, not just by their applications but by their intrinsic energetic and metabolic properties. *B. prionitis*, or Sareyaka, is well-documented in this tradition, with its identity, properties, and uses clearly delineated.

3.1. Classical Identity and Synonyms: Names as Functional Descriptors

In Ayurveda, Sareyaka is recognized in several varieties based on flower color. *Barleria prionitis*, with its characteristic yellow flowers, is specifically identified as *Pita-Saireyaka* (yellow Sareyaka) or Kurantaka.¹⁰ Beyond these classifications, the plant is known by several other Sanskrit synonyms that are not merely arbitrary labels but are functional descriptors, acting as etymological signposts to its primary therapeutic actions.

This sophisticated, observation-based nomenclature provides a direct bridge to the plant's modern pharmacological validation. Two names are particularly illustrative:

- **Vajradanti:** This is perhaps its most famous synonym, a compound of two Sanskrit words: *vajra* (meaning diamond or thunderbolt) and *danti* (meaning teeth).¹² The name literally translates to "that which makes teeth as strong as diamonds," pointing unequivocally to its principal use in strengthening gums and teeth and treating a host of dental ailments.¹² This traditional name has been so influential that it is now a common brand name for herbal dental care products in India.
- **Sahachara:** This name translates to "walking together" or "companion," an allusion to its profound efficacy in treating disorders that impair mobility.⁶ It is a primary herb for managing *Vata* disorders, which in Ayurveda govern movement and are associated with conditions like arthritis, sciatica, back pain, and general stiffness of the limbs. Formulations named *Sahacharadi* (meaning 'Sahachara and others') are staples in the Ayurvedic treatment of such musculoskeletal and neurological conditions.¹⁰

This system of naming serves as a powerful mnemonic device, encoding the plant's key medicinal roles directly into its identity. It is crucial, however, to ensure correct botanical identification, as some commercial sources have erroneously equated Vajradanti with *Coriandrum sativum* (Coriander), a completely different plant with different properties, highlighting the risks of relying on common names without proper botanical verification.¹⁵

3.2. Ayurvedic Properties (Dravyaguna)

Dravyaguna is the branch of Ayurveda that deals with the properties and actions of medicinal substances. It provides a framework for understanding how a substance will interact with the body's physiological systems. The Ayurvedic properties of Sareyaka are central to its therapeutic application.

Table 2: Ayurvedic Properties (Dravyaguna) of Sareyaka (*B. prionitis*)

Property	Ayurvedic Term	Value
Taste	<i>Rasa</i>	<i>Tikta</i> (Bitter), <i>Katu</i> (Pungent)
Qualities	<i>Guna</i>	<i>Laghu</i> (Light), <i>Ruksha</i> (Dry)
Potency	<i>Virya</i>	<i>Ushna</i> (Hot)
Post-digestive Effect	<i>Vipaka</i>	<i>Katu</i> (Pungent)
Action on Doshas	<i>Dosha Karma</i>	<i>Kapha-Vatahara</i> (Pacifies Kapha and Vata)

The combination of these properties explains its use in Ayurveda. The *Tikta* (bitter) and *Katu* (pungent) tastes are known to have antimicrobial, anti-inflammatory, and detoxifying effects. The *Laghu* (light) and *Ruksha* (dry) qualities counteract the heavy, oily nature of *Kapha dosha*, making it effective in conditions with excess mucus or swelling. Its most significant property is its *Ushna Virya* (hot potency), which gives it a heating effect on the body. This potency is key to pacifying *Vata dosha*, which is cold and dry by nature. The heat helps to alleviate pain, reduce stiffness, improve circulation, and stimulate metabolism (*Agni*). The *Katu Vipaka* (pungent post-digestive effect) further supports its action in clearing channels and reducing *Kapha*. Therefore, its overall effect is to pacify conditions arising from aggravated *Kapha* and *Vata*, which aligns perfectly with its use in respiratory disorders, joint pain, and certain types of skin diseases. This energetic profile provides a crucial framework for Ayurvedic practitioners to determine its suitability for a patient's specific constitution (*Prakriti*) and imbalance (*Vikriti*).

3.3. Classical Texts and Formulations

Sareyaka is mentioned in the great classical treatises (*Brihatrayi*) and later medieval lexicons (*Nighantus*), confirming its long-standing role in Ayurvedic medicine. It is referenced in the *Charaka Samhita* and *Sushruta Samhita* for its use in treating conditions like *Visarpa* (a herpetic skin condition) and *Vata* disorders.¹¹ Later texts like the 16th-century *Bhavaprakasha Nighantu* further detail its properties and uses.¹⁷

Its importance is underscored by its inclusion as a key ingredient in several classical polyherbal formulations:

- **Kantaka Panchamula:** This is a formulation comprising five "thorny" plants: *Karmarda* (*Carissa carandas*), *Gokshura* (*Tribulus terrestris*), *Saireyaka* (*Barleria prionitis*), *Shatavari* (*Asparagus racemosus*), and *Hinstra* (*Capparis sepiaria*). It is traditionally used in the management of *Prameha*, a class of urinary disorders that includes diabetes mellitus.¹⁹ In this context, Saireyaka's role is attributed to its anti-inflammatory, antimicrobial, and diuretic properties, which help reduce the chronic inflammation associated with metabolic disorders and prevent secondary urinary tract infections.¹⁹
- **Sahacharadi Kashayam and Sahacharadi Taila:** These are among the most famous formulations for neurological and musculoskeletal ailments. As the lead herb (*Sahachara*), *B. prionitis* is combined with other herbs like *Suradaru* (*Cedrus deodara*) and *Sunthi* (*Zingiber officinale*).¹⁴ These

preparations, used as decoctions (*Kashayam*) for internal use or medicated oils (*Taila*) for external massage and other *Panchakarma* procedures like *Basti* (enema), are specifically indicated for *Vata* conditions like *Gridhrasi* (sciatica), paraplegia, backache, and tremors.¹⁰ Its *Ushna Virya* is central to its action in these formulations, helping to alleviate pain and stiffness.

4. Ethnomedicinal and Traditional Therapeutic Applications

The ethnomedicinal record of *Barleria prionitis* is vast and varied, reflecting its widespread availability and deep integration into the folk healing traditions of numerous cultures. Every part of the plant—from its roots to its flowers—is utilized, often in simple preparations like pastes, juices, and decoctions. This rich repository of traditional knowledge has been the primary source of leads for modern pharmacological investigation. A systematic review of its ethnomedical uses reveals a consistent pattern of application across different geographical regions for a core set of ailments.²

- **Oral and Dental Health:** This is arguably its most well-known application. The leaves are chewed directly to relieve toothache, and a mouthwash made from root tissue is used to treat bleeding gums.² This practice is common throughout its native range.
- **Inflammatory and Painful Conditions:** The plant is widely used to treat joint pain, rheumatism, and sciatica. The whole plant may be used, or a paste of the roots can be applied externally to disperse boils and glandular swellings.²
- **Skin Diseases:** Its application for skin ailments is extensive. A paste of the leaves is applied to wounds, boils, and rashes to promote healing and prevent infection.²⁴ Leaf juice is used on lacerated soles of the feet, a common issue in rural communities during rainy seasons.²
- **Respiratory and Febrile Conditions:** A juice made from the leaves, often mixed with honey, is given to children to relieve fever and catarrhal affections like coughs and colds.² The dried bark is used as an expectorant in whooping cough, and an ash of the whole plant mixed with honey is a traditional remedy for bronchial asthma.²
- **Gastrointestinal and Systemic Disorders:** Leaf juice is used for stomach disorders and jaundice.² The roots are considered a diuretic and tonic, employed in cases of urinary infections, dropsy (edema), and hepatic obstruction.²
- **Cosmetic and Other Uses:** An oil extract of the plant is traditionally recommended for arresting the graying of hair.² The flowers are used for treating migraines and seminal disorders.²

The following table organizes this extensive data, providing a clear overview that can guide researchers toward the most promising areas for phytochemical and pharmacological screening.

Table 3: Summary of Traditional Uses of Different Parts of *Barleria prionitis* L.

Plant Part	Traditional Indication	Form of Use
Leaves	Toothache, Bleeding gums, Mouth ulcers	Chewed, Juice, Paste
	Fever, Cough, Catarrh	Juice (with honey), Decoction
	Skin infections, Wounds, Boils, Rashes	Paste, Juice (topical)
	Joint pain, Rheumatism	Poultice, Juice
	Urinary infections, Stomach disorders	Juice
Root	Boils, Glandular swellings	Paste (topical)
	Fever, Jaundice, Dropsy (Edema)	Decoction, Powder
	Diuretic, Tonic	Decoction
	Whooping cough, Snakebite	Decoction, Formulation

Bark	Whooping cough, Cough	Powder, Juice
Flowers	Migraine, Internal abscesses, Edema	Internal use (formulation)
Whole Plant	Bronchial asthma	Ash (with honey)
	Sciatica, Stiffness of limbs, Gout	Formulation, Paste (topical)
	Arresting graying of hair	Oil extract

5. Phytochemical Landscape: The Source of Therapeutic Activity

The therapeutic efficacy of any medicinal plant resides in its complex mixture of secondary metabolites. Research into *Barleria prionitis* has unveiled a rich and diverse phytochemical profile, providing the chemical basis for its wide-ranging medicinal properties. The isolation and characterization of these compounds act as a crucial bridge, connecting the plant's traditional uses to its observable pharmacological effects.

The major classes of bioactive compounds identified in various parts of *B. prionitis* include iridoid glycosides, flavonoids, terpenoids, and phenylethanoid glycosides.³

- **Iridoid Glycosides:** This class stands out as one of the most significant contributors to the plant's bioactivity. Key compounds that have been repeatedly isolated and studied include **barlerin**, **acetylbarlerin**, **shanzhiside methyl ester**, and a group of compounds named **prionisides** (A, B, and C).¹⁴ These molecules are frequently found in the leaves and aerial parts of the plant.
- **Flavonoids:** These polyphenolic compounds are well-known for their antioxidant and anti-inflammatory properties. *B. prionitis* contains several flavonoids, including **luteolin**, **scutellarein**, and their various glycosidic forms, such as **scutellarein-7-neohesperidoside**, primarily isolated from the flowers and leaves.¹⁴
- **Terpenoids and Sterols:** This group includes **lupeol**, a pentacyclic triterpene with known anti-inflammatory and anticancer activities, and **β -sitosterol**, a common phytosterol with cholesterol-lowering and immunomodulatory effects.²² These are generally distributed throughout the plant.
- **Phenylethanoid Glycosides:** Compounds like **verbascoside** and **barlerinoside** have been isolated from the aerial parts. Verbascoside, in particular, is noted for its potent antioxidant and neuroprotective properties.¹⁴
- **Other Constituents:** The plant also contains a variety of other compounds that contribute to its overall therapeutic profile, including alkaloids, tannins, saponins, phenolic acids, and fatty acids.³

Table 4: Major Phytochemical Constituents of *Barleria prionitis* L.

Chemical Class	Specific Compound(s)	Plant Part(s) of Isolation
Iridoid Glycosides	Barlerin, Acetylbarlerin, Shanzhiside methyl ester, Prioniside A/B/C, Lupuloside	Leaves, Aerial Parts, Stem
Flavonoids	Luteolin, Scutellarein, Scutellarein-7-neohesperidoside	Flowers, Leaves
Phenylethanoid Glycosides	Verbascoside, Barlerinoside	Aerial Parts
Terpenoids & Sterols	Lupeol, β -sitosterol, Balarenone, Pipataline	Aerial Parts, Whole Plant
Phenolics & Tannins	Gallic acid, Ellagic acid	Whole Plant, Leaves
Alkaloids & Saponins	-	Whole Plant, Leaves, Root

A closer analysis of the phytochemical and pharmacological data reveals a clear convergence point: the iridoid glycosides. This class of compounds appears to be the biochemical nexus responsible for many of the plant's most significant and traditionally recognized therapeutic effects. Scientific literature consistently highlights iridoids as major constituents.¹⁴ Concurrently, pharmacological studies repeatedly link either these specific compounds or iridoid-rich fractions of the plant extract to a core set of activities, including potent anti-inflammatory and anti-arthritis effects²², significant hepatoprotective action²², anti-diarrheal properties²⁵, and antiviral activity.³ This establishes a robust structure-activity relationship, providing a molecular-level validation for the traditional use of Sareyaka in treating inflammatory conditions (*Vata roga*), liver disorders (*Kamala*), and various infections. This strong correlation suggests that standardizing *B. prionitis* extracts based on their iridoid glycoside content could be a highly effective strategy for producing consistent and potent phytopharmaceutical products.

6. Pharmacological Validation of Traditional Claims

The true measure of a traditional medicine's value in the modern world lies in its scientific validation. Over the past few decades, *Barleria prionitis* has been subjected to extensive pharmacological investigation, and the results have been remarkable. A significant number of its traditional uses have been substantiated through rigorous in-vitro and in-vivo experimental models, confirming the empirical wisdom of ancient healers.

6.1. Anti-inflammatory and Anti-arthritis Activity

Traditional Link: This is a direct validation of its use as *Sahachara* for *Vata* disorders, particularly those involving pain and inflammation such as arthritis (*Amavata*), rheumatism, and joint stiffness.

Evidence: Numerous studies have confirmed the potent anti-inflammatory and anti-arthritis properties of *B. prionitis*. In-vivo studies using the carrageenan-induced paw edema model in rats, a standard test for acute inflammation, have shown that various extracts of the plant significantly reduce swelling.²² A hydro-alcoholic extract fraction ("TAF") demonstrated significant activity against inflammation induced not only by carrageenan but also by histamine and dextran.²⁹ Crucially, this effect was maintained in adrenalectomized rats, indicating that its mechanism of action is direct and not mediated through the pituitary-adrenal axis.²⁹ In chronic inflammation models, such as the complete Freund's adjuvant (CFA)-induced arthritis model in rats, extracts of *B. prionitis* have been shown to reduce paw edema, protect against bone loss, and improve hematological parameters.²² The mechanism is believed to involve the inhibition of cyclooxygenase (COX-1 and COX-2) enzymes, which reduces the synthesis of inflammatory prostaglandins.²² The iridoid glycosides, including barlerin and shanzhiside methyl ester, are strongly implicated as the primary anti-inflammatory agents.¹⁴

6.2. Antimicrobial and Anti-dental Activity

Traditional Link: This research validates the plant's most famous name, "Vajradanti," and its widespread use for toothache, bleeding gums, mouth ulcers, and skin infections (*Kustha*).

Evidence: In-vitro studies have demonstrated that extracts of *B. prionitis* possess broad-spectrum antimicrobial activity. Of particular note is its potent action against oral pathogens responsible for dental caries and periodontal disease. Methanolic extracts of the bark have shown significant inhibitory activity against *Streptococcus mutans*, the primary causative agent of dental plaque and cavities, as well as *Staphylococcus aureus* and the fungus *Candida albicans*, which is associated with oral thrush.¹³ The plant's extracts are also effective against skin pathogens like *S. aureus* and bacteria that cause gastrointestinal infections, such as *E. coli* and *Vibrio cholerae*.²² The phytochemicals responsible for these effects include pentacyclic triterpenes, which inhibit bacterial adhesion, and other compounds like balarenone and pipataline.¹³ This strong scientific evidence provides a clear rationale for its traditional use in oral hygiene and for treating infections.

6.3. Antioxidant, Hepatoprotective, and Nephroprotective Effects

Traditional Link: These activities support its classical use as a tonic (*Rasayana*), for treating jaundice (*Kamala*), and for managing urinary disorders.

Evidence: Extracts from various parts of the plant, especially the leaves and stems, have demonstrated significant antioxidant activity in various assays, effectively scavenging free radicals.⁵ This antioxidant capacity is attributed to its rich content of phenolic and flavonoid compounds.¹³ This activity is foundational to its protective effects on vital organs. Studies have shown that iridoid glycoside-enriched fractions from the leaves and stems offer significant hepatoprotection against toxins like carbon tetrachloride and paracetamol in animal models. The extracts were able to reduce elevated liver enzymes (ALT, AST) and restore hepatic glutathione levels, a key endogenous antioxidant.²² More recently, research has highlighted its remarkable nephroprotective potential. In a study on doxorubicin-induced acute kidney injury in rats, extracts of *B. prionitis* significantly reversed markers of kidney damage, reduced inflammation, and modulated apoptosis in kidney tissues. This suggests its potential as a valuable adjuvant therapy to mitigate the toxic side effects of chemotherapy drugs.³⁰

6.4. Analgesic and Antinociceptive Properties

Traditional Link: This directly corroborates its folk use for alleviating various types of pain, most notably toothache and joint pain.

Evidence: The analgesic (pain-relieving) effects of *B. prionitis* have been confirmed in animal models. Flower extracts have been shown to significantly increase the pain threshold in tests like the hot plate and tail-flick assays and reduce the number of writhings in the acetic acid-induced writhing test in mice.³ This antinociceptive activity, combined with its anti-inflammatory properties, explains its effectiveness in managing painful inflammatory conditions. The bioactive compounds responsible likely include glycosides and tannins, which can modulate pain receptors and interfere with pain signaling pathways.¹³

6.5. Other Validated Activities

Research has also uncovered other promising therapeutic activities that align with its traditional uses:

- **Antidiabetic Activity:** Alcoholic extracts of the leaves have been shown to lower blood glucose levels and increase serum insulin in diabetic rats, supporting its inclusion in the *Kantaka Panchamula* formulation for *Prameha*.³
- **Antifertility Activity:** Root extracts have demonstrated antifertility effects in male albino rats, reducing sperm count and motility. This is a significant finding that warrants further investigation for its potential in developing male contraceptive agents.²²
- **Antiviral Activity:** Two iridoid glycosides isolated from the plant showed potent antiviral activity against the Respiratory Syncytial Virus (RSV), a common cause of respiratory illness, especially in children.³ This supports its traditional use for catarrhal affections.

7. Quality Control, Safety, and Toxicology

For a traditional herb to be successfully integrated into modern therapeutic practice, it must meet stringent standards of quality, safety, and efficacy. This requires robust methods for standardization and a clear understanding of its toxicological profile.

7.1. Pharmacognostic Standardization and Adulteration

The efficacy of an herbal medicine is contingent upon the authenticity and quality of its raw material. Adulteration and substitution are significant threats to the safety and reliability of Ayurvedic products. In the case of *B. prionitis*, a known issue, particularly in South India, is its substitution with the roots of *Nilgiranthus heyneanus* (Nees) Bremek., another plant from the Acanthaceae family.¹⁰ While perhaps used as a local substitute, such practices can lead to a lack of therapeutic effect or even adverse reactions if the chemical profiles of the plants differ significantly.

This challenge highlights the critical role of modern science in preserving the integrity of traditional medicine. Pharmacognosy provides the necessary tools to combat such adulteration. The detailed anatomical and microscopic studies of *B. prionitis* serve a direct practical purpose in quality control.¹⁰ The presence of specific diagnostic markers, such as the characteristic paired cystoliths, diacytic stomata, and the anomalous secondary growth pattern in the root and stem, can be used to create a definitive anatomical fingerprint for the genuine drug. Furthermore, physicochemical standardization, which involves determining parameters like total ash, acid-insoluble ash, and water-soluble extractive values, provides a quantitative measure of quality and purity.³³ These scientific methods are not merely descriptive exercises; they are essential for ensuring that the *B. prionitis* used in commercial formulations is authentic, potent, and safe, thereby upholding the principles of Ayurveda in a modern context.

7.2. Toxicological Profile and Safety Assessment

A thorough safety assessment is paramount for any therapeutic agent. The available toxicological data for *Barleria prionitis* suggests a high margin of safety. Acute toxicity studies conducted in animal models have found the oral lethal dose (LD50) of its extracts to be very high. For the 'TAF' fraction, the oral LD50 in mice was found to be greater than 3000 mg/kg, with no signs of mortality or abnormality observed after administration.²⁹ The intraperitoneal LD50 was found to be 2530 mg/kg, which is also considered low toxicity.²⁹

The general consensus from multiple reviews is that the plant possesses low toxicity and is safe for therapeutic use at recommended doses.⁵ This safety profile is further reinforced by studies demonstrating its organo-protective effects. Far from being toxic, the plant has been shown to protect the liver and kidneys from potent chemical toxins like doxorubicin, paracetamol, and carbon tetrachloride.²² This evidence strongly supports its traditional use as a safe and effective remedy. However, as with any bioactive substance, it is always advisable to use it under the guidance of a qualified healthcare professional.

8. Conclusion

Barleria prionitis L., the Sareyaka of Ayurvedic texts, stands as a powerful testament to the enduring relevance of traditional medical wisdom. This comprehensive review reveals a remarkable congruence between its classical identity and uses, developed over centuries of empirical observation, and its modern, evidence-based pharmacological profile. The plant's journey from tradition to therapy is not one of replacement but of validation and elucidation. The very names given to it in Sanskrit—*Vajradanti* for dental health and *Sahachara* for mobility disorders—have been shown to be astute descriptors of its primary therapeutic actions, now confirmed by its potent antimicrobial, anti-inflammatory, and analgesic properties demonstrated in scientific studies.

The phytochemical investigation has identified iridoid glycosides as the likely chemical backbone of its most significant bioactivities, providing a molecular basis for its efficacy in treating inflammatory conditions. The alignment is striking: the *Ushna Virya* (hot potency) described in Ayurveda, which pacifies the cold nature of *Vata* disorders like arthritis, finds its modern parallel in the anti-inflammatory and analgesic mechanisms of the plant's chemical constituents. The validation of its traditional uses for skin, liver, and urinary tract ailments through its proven antimicrobial, hepatoprotective, and nephroprotective effects further solidifies this bridge between ancient knowledge and modern science.

The future of *Barleria prionitis* in medicine appears bright, but further research is essential to unlock its full potential. Key future perspectives include:

1. **Comparative Subspecies Research:** Conducting detailed comparative phytochemical and pharmacological studies on the three recognized subspecies (*appressa*, *induta*, and *pubiflora*) is a high priority. This will clarify whether they are therapeutically interchangeable and is crucial for establishing global quality control standards.
2. **Mechanism of Action Studies:** While many activities have been confirmed, the precise molecular mechanisms of more of its isolated bioactive compounds need to be elucidated. This will help in optimizing their therapeutic use and identifying new applications.
3. **Clinical Trials and Product Development:** There is a pressing need to move from preclinical animal models to well-designed human clinical trials. Such trials could validate its efficacy for conditions like osteoarthritis, gingivitis, and as a supportive nephroprotective agent during chemotherapy, paving the way for the development of standardized, evidence-based phytopharmaceutical products.

Ultimately, *Barleria prionitis* serves as an exemplary model for the scientific exploration of Ayurveda's vast pharmacopoeia. It demonstrates that by integrating the rich, nuanced framework of traditional knowledge with the rigorous methodologies of modern science, we can uncover safe, effective, and accessible therapeutic solutions for the health challenges of today and tomorrow.

References

1. Flora of China Editorial Committee. *Barleria prionitis*. In: Flora of China. Vol. 19. Beijing: Science Press & St. Louis: Missouri Botanical Garden Press; 2015. ¹
2. Balkwill M-J, Balkwill K. A preliminary analysis of distribution patterns in a large, pantropical genus, *Barleria* L. (Acanthaceae). *J Biogeogr*. 1997;24(1):95-110. ¹
3. Balkwill M-J, Balkwill K. The genus *Barleria* (Acanthaceae) in southern Africa. In: Timberlake J, Kativu S, editors. *African Plants: Biodiversity, Taxonomy and Uses*. Kew: Royal Botanic Gardens; 1998. p. 439-459. ¹
4. USDA-ARS. Germplasm Resources Information Network (GRIN). Online Database. Beltsville, Maryland, USA: National Germplasm Resources Laboratory. [Online]. Available: <http://www.ars-grin.gov/>. [Accessed: 2015]. ¹
5. Weeds of Australia. *Barleria prionitis*. Biosecurity Queensland Edition. [Online]. Available: http://keyserver.lucidcentral.org/weeds/data/03030800-0b07-490a-8d04-0605030c0f01/media/Html/Barleria_prionitis.htm. [Accessed: 2015]. ¹
6. Linnaeus C. *Species Plantarum*. 1st ed. Stockholm: Laurentius Salvius; 1753. ⁷
7. Brummitt RK, Wood JRI. A new combination in *Barleria* (Acanthaceae) from Arabia. *Kew Bull*. 1983;38(3):436. ⁷
8. Shendage SM, Yadav SR. Revision of the genus *Barleria* (Acanthaceae) in India. *Rheede*. 2010;20(2):81-130. ⁷
9. Collenette S. *Wildflowers of Saudi Arabia*. Riyadh: National Commission for Wildlife Conservation and Development (NCWCD); 1999. ⁷
10. Govaerts R. *World Checklist of Seed Plants*. Vol. 2(1, 2). Deurne: MIM; 1996. p. 1-492. ⁷
11. Pullaiah T, et al. *Flora of Eastern Ghats*. Vol. 4. New Delhi: Regency Publications; 2011. ⁶
12. Ellis JL. *Flora of Nallamalais*. Vol. 2. Calcutta: Botanical Survey of India; 1990. ⁶
13. Saxena HO, Brahmam M. *The Flora of Orissa*. Vol. 3. Bhubaneswar: Orissa Forest Development Corporation Ltd.; 1995. ⁶
14. Rao RS, et al. *Flora of West Godavari District*. Meerut: International Book Distributors; 1986. ⁶
15. Rao RS, Sreeramulu SH. *Flora of Srikakulam District*. Meerut: International Book Distributors; 1986. ⁶
16. Matthew KM. *The Flora of Tamil Nadu Carnatic*. Vol. 3(1). Madras: Diocesan Press; 1983. ⁶
17. Sasidharan N. *Flowering plants of Kerala*. DVD, V 2. Peechi: Kerala Forest Research Institute; 2011. ⁶
18. NEERI. Porcupine Flower / Vajradanti. NEERI at Home. [Online]. Available: <https://neeriathehome.neeri.res.in/biodiversity/Vajradanti.php>. [Accessed: 2024]. ⁹
19. Lucid Central. Weeds of Australia - *Barleria prionitis*. [Online]. Available: https://keyserver.lucidcentral.org/weeds/data/media/Html/barleria_prionitis.htm. [Accessed: 2024]. ⁸

20. NParks Board, Singapore. Flora & Fauna Web - *Barleria prionitis* L. [Online]. Available: <https://www.nparks.gov.sg/florafaunaweb/flora/5/6/5624>. [Accessed: 2024]. ⁴
21. Patgiri B, et al. Systemic hemodynamic changes following Sarvanga Swedana (passive whole body heat therapy) in Ayurveda. *Anc Sci Life*. 2013;33(1):36-40. ³⁴
22. Utpala Ayurdhama. Sarvanga Parisheka. [Online]. Available: <https://utpalaayurdhama.com/treatment/sarvanga-parisheka/>. [Accessed: 2024]. ³⁵
23. Dabur. Vajradanti Plant. Dabur Ayurveda. [Online]. Available: <https://www.dabur.com/ayurveda/ayurvedic-medicinal-plants/vajradanti-plant>. [Accessed: 2024]. ¹⁵
24. Zandu Care. Vajradanti: A Complete Guide to Ayurveda. [Online]. Available: <https://zanducare.com/blogs/exploring-ayurveda/vajradanti-guide-to-ayurveda>. [Accessed: 2024]. ¹³
25. Singh R, et al. A review on Kurantaka (*Barleria prionitis* Linn.). *World J Pharm Res*. 2024;13(9):123-134. ¹¹
26. Arogya Yoga School. Health Benefits of Vajradanti (*Barleria prionitis*). [Online]. Available: <https://www.arogyayogaschool.com/blog/health-benefits-of-vajradanti-barleria-prionitis/>. [Accessed: 2024]. ¹²
27. Jadhav P, Patil P. A review on the management of Prameha through Kantaka Panchamula. *JETIR*. 2024;11(8):f530-f534. ¹⁹
28. Charaka. Charaka Samhita. Chikitsa Sthana, Chapter 28, Verse 57. ¹⁶
29. Sushruta. Sushruta Samhita. Nidana Sthana, Chapter 1, Verse 75. ¹⁶
30. Vagbhata. Ashtanga Hridayam. ¹⁶
31. Sharma A, et al. A comprehensive review of Bhavaprakasha Nighantu: a 16th-century Ayurvedic lexicon. *Int J Ayur Pharm Res*. 2024;12(5):1-10. ¹⁷
32. Chuneekar KC. Bhavaprakasha Nighantu of Bhavamishra. Varanasi: Chaukhambha Bharati Academy; 2010. ¹⁷
33. Mishra B. Bhavaprakasha. Varanasi: Chaukhambha Sanskrit Sansthan; 2007. ¹⁸
34. Banerjee D, Maji AK, Mahapatra S, Banerji P. *Barleria prionitis* Linn.: a review of its traditional uses, phytochemistry, pharmacology and toxicity. *Res J Phytochem*. 2012;6(2):31-41. ²
35. Nakra Ayurveda. Saireyak (*Barleria prionitis*). [Online]. Available: <https://www.nakraayurveda.com/saireyak-barleria-prionitis/>. [Accessed: 2024]. ²⁶
36. Khare CP. Indian Medicinal Plants: An Illustrated Dictionary. New Delhi: Springer; 2007. ²
37. Daniel M. Medicinal Plants: Chemistry and Properties. Enfield, NH: Science Publishers; 2006. ²
38. Aneja KR, Joshi R, Sharma C. *Barleria prionitis* L.: a review on its ethnobotany, phytochemistry, pharmacology and toxicity. *J Ethnopharmacol*. 2010;128(2):255-68. ²
39. Shukla R, et al. Ethnobotanical studies on some medicinal plants of Chitrakoot region, Madhya Pradesh, India. *J Med Plants Res*. 2011;5(8):1364-1368. ²
40. Khadse CD, Kakde RB. Ethnobotanical survey of some medicinal plants from Akola district, Maharashtra. *Int J Pharm Biol Sci*. 2011;1(3):319-323. ²
41. Gupta AK, et al. Pharmacognostical and pharmacological profile of *Barleria prionitis* root. *Res J Pharmacogn Phytochem*. 2011;3(3):121-125. ²⁷
42. Jaiswal SK, et al. A review on *Barleria prionitis* Linn. *Bull Env Pharmacol Life Sci*. 2020;9(4):163-174. ²⁵
43. Chen JL, et al. Anti-viral iridoid glycosides from the medicinal plant *Barleria prionitis*. *J Nat Prod*. 1998;61(10):1295-1297. ²⁵
44. Manjula M, et al. Phytochemical analysis and in vitro antioxidant activity of *Barleria prionitis* and *Phyllanthus acidus*. *World J Pharm Res*. 2023;12(10):22453-22462. ²¹
45. Mukherjee PK. Quality Control of Herbal Drugs: An Approach to Evaluation of Botanicals. New Delhi: Business Horizons; 2002. ²¹
46. Chaudhuri RD. Herbal Drug Industry. New Delhi: Eastern Publishers; 1996. ²¹
47. Kokate CK. Practical Pharmacognosy. 4th ed. New Delhi: Vallabh Prakashan; 1994. ²¹
48. Kadam PV, et al. Phytochemical screening and standardization of extracts from *Barleria prionitis* leaves. *Int J Pharm Sci*. 2024;16(10):1-6. ³³

49. Verma S, et al. A review: traditional ethnomedicinal utilization, pharmacological properties and phytochemistry of *Barleria prionitis* Linn. Int J Pharm Sci Rev Res. 2017;44(2):19-26. ²²
50. Singh B, et al. Anti-inflammatory activity of *Barleria prionitis* Linn. and *Celsia coromandeliana* Vahl. in rats. J Ethnopharmacol. 2003;85(2-3):147-152. ²²
51. Dheer R, et al. A review on pharmacological and phytochemical profile of *Barleria prionitis* Linn. (Vajradanti). Int J Curr Trends Res. 2023;12(12):543-552. ³
52. Prabha T, et al. Anatomical characterization of *Barleria prionitis* Linn. Biological Forum. 2012;4(1):1-6. ¹⁰
53. Chopra RN, et al. Glossary of Indian Medicinal Plants. New Delhi: CSIR; 1996. ¹⁰
54. Sharma PC, et al. Database on Medicinal Plants Used in Ayurveda. Vol. 1. New Delhi: CCRAS; 2000. ¹⁰
55. Singh B, et al. Hepatoprotective activity of *Barleria prionitis* Linn. against carbon tetrachloride induced hepatotoxicity in rats. Crit Rev Food Sci Nutr. 2005;45(7-8):551-556. ¹⁰
56. Shantha TR, et al. Pharmacognostical studies on the root of *Nilgiranthus heyneanus* (Nees) Bremek. and its comparison with *Barleria prionitis* Linn. Anc Sci Life. 1988;8(1):42-50. ¹⁰
57. Kumar S, et al. A review on phytochemistry and pharmacology of *Barleria cristata*. Pharm Biomed Res. 2020;6(4):1-8. ³²
58. Amarasiri SS, et al. *Barleria prionitis* L. extracts ameliorate doxorubicin-induced acute kidney injury via modulation of oxidative stress, inflammation, and apoptosis. J Tradit Complement Med. 2023;13(5):500-510. ³⁰
59. Gupta A, et al. A review on *Barleria prionitis*: An underutilized medicinal plant. World J Pharm Res. 2024;13(6):4042-4055. ⁵
60. Singh B, et al. Antiinflammatory and antiarthritic activity of a fraction from *Barleria prionitis* Linn. Phytother Res. 2003;17(3):262-266. ²⁹
61. Duke JA. Handbook of Biologically Active Phytochemicals and Their Activities. Boca Raton, FL: CRC Press; 1992. ²³
62. Uphof JC Th. Dictionary of Economic Plants. 2nd ed. Lehre: Verlag von J. Cramer; 1968. ²³
63. National Innovation Foundation. Herbal treatment for skin disease. [Online]. Available: <https://innovation.nif.org.in/innovation/detail/herbal-treatment-for-skin-disease/28688>. [Accessed: 2024]. ²⁴
64. Parrotta JA. Healing Plants of Peninsular India. Wallingford, UK: CABI Publishing; 2001. ⁴
65. Burkill IH. A Dictionary of the Economic Products of the Malay Peninsula. Vol. 1. Kuala Lumpur: Ministry of Agriculture and Co-operatives; 1985. ⁴
66. Prakruti. Herbal Cosmetics. [Online]. Available: <http://www.prakruti.com>. [Accessed: 2002]. ⁴
67. Probiotics New Zealand. Herbal Hair Care. [Online]. Available: <http://www.probiotics.co.nz>. [Accessed: 2002]. ⁴
68. Vaipani. Ayurvedic Products. [Online]. Available: <http://www.vaipani.com>. [Accessed: 2002]. ⁴
69. India Flora. *Barleria prionitis* L. [Online]. Available: <https://indiaflora-ces.iisc.ac.in/FloraPeninsular/plants.php?name=Barleria%20prionitis>. [Accessed: 2024]. ⁶
70. Bhadane R, Charde R. *Barleria prionitis*: An Ethnomedicinally Important Plant. J Ethnopharmacol. 2019;240:111945. ¹⁹
71. Gupta R, Gupta N. *Asparagus racemosus* (Shatavari): A Review on its Phytochemistry and Pharmacology. J Pharmacogn Phytochem. 2018;7(4):123-130. ¹⁹
72. Kumar S, Ali M. A review on phytochemistry and pharmacology of *Tribulus terrestris*. J Pharmacogn Phytochem. 2020;9(3):145-152. ¹⁹
73. Banerjee S, et al. GC-MS analysis of ayurvedic medicine Sahachardi Kashayam. J Chem Pharm Res. 2012;4(10):4634-4638. ¹⁴
74. Sudheer A, Praveen B. A review on ethnomedicinal uses, phytochemistry and pharmacology of *Barleria* species. J Pharmacogn Phytochem. 2021;10(1):10-18. ¹⁴
75. Al-Snafi AE. The pharmacological importance of *Barleria* species (Acanthaceae): a review. IOSR J Pharm. 2018;8(10):51-63. ¹⁴
76. Singh B, et al. Anti-inflammatory activity of *Barleria prionitis* and *Barleria cristata* roots. J Ethnopharmacol. 2005;98(3):281-285. ¹⁴
77. Khobragade CN, et al. In vitro antioxidant activity of methanolic extract of *Barleria prionitis* Linn. Int J PharmTech Res. 2010;2(2):1311-1316. ²⁵
78. Singh B, et al. Antidiarrhoeal activity of iridoid glycosides from *Barleria prionitis* Linn. in rats. J Ethnopharmacol. 2005;96(1-2):179-185. ²⁵
79. Dheer R, Bhatia D. Analgesic activity of *Barleria prionitis* Linn. flower extract. Indian J Exp Biol. 2005;43(3):284-287. ²⁵

80. Jayatilaka KAPW, et al. *Barleria prionitis* L. (Acanthaceae) as a potential source of anticancer agents: a review. J Ethnopharmacol. 2022;285:114841. ³⁰

Works cited

1. Barleria prionitis (porcupine flower) | CABI Compendium, accessed on August 4, 2025, <https://www.cabidigitallibrary.org/doi/full/10.1079/cabicompendium.8510>
2. Barleria prionitis Linn.: A Review of its Traditional Uses ..., accessed on August 4, 2025, <https://scialert.net/fulltext/?doi=rjphyto.2012.31.41>
3. PHYTOCHEMICALS EXPLORATION ... - IJCRT, accessed on August 4, 2025, <https://ijcrt.org/papers/IJCRT2312543.pdf>
4. Barleria prionitis - NParks, accessed on August 4, 2025, <https://www.nparks.gov.sg/florafaunaweb/flora/5/6/5624>
5. A review on, pharmacological activities of barleria prionitis linn, accessed on August 4, 2025, <https://www.wisdomlib.org/science/journal/world-journal-of-pharmaceutical-research/d/doc1374042.html>
6. Barleria prionitis L. - Herbarium JCB, accessed on August 4, 2025, <https://indiaflora-ces.iisc.ac.in/FloraPeninsular/plants.php?name=Barleria%20prionitis>
7. Barleria prionitis - Wikipedia, accessed on August 4, 2025, https://en.wikipedia.org/wiki/Barleria_prionitis
8. Barleria prionitis - Lucid key, accessed on August 4, 2025, https://keyserver.lucidcentral.org/weeds/data/media/Html/barleria_prionitis.htm
9. CSIR-NEERI Biodiversity Portal, accessed on August 4, 2025, <https://neeriathome.neeri.res.in/biodiversity/Vajradanti.php>
10. Anatomical Characterization of Barleria prionitis ... - Research Trend, accessed on August 4, 2025, [https://www.researchtrend.net/bfij/biological_forum_4\(1\)_2012/1%20DR%20PRABHA.pdf](https://www.researchtrend.net/bfij/biological_forum_4(1)_2012/1%20DR%20PRABHA.pdf)
11. Kurantaka (barleria prionitis linn) in vedic and samhita kaal ..., accessed on August 4, 2025, <https://www.wisdomlib.org/science/journal/world-journal-of-pharmaceutical-research/d/doc1379780.html>
12. Amazing health benefits of Vajradanti - Barleria prionitis, accessed on August 4, 2025, <https://www.arogyayogaschool.com/blog/health-benefits-of-vajradanti-barleria-prionitis/>
13. Vajradanti [Barleria] Complete Guide to the Ayurvedic Herb, accessed on August 4, 2025, <https://zanducare.com/blogs/exploring-ayurveda/vajradanti-guide-to-ayurveda>
14. Barleria prionitis Linn.: A Review of its Traditional Uses ..., accessed on August 4, 2025, https://www.researchgate.net/publication/233753874_Barleria_prionitis_Linn_A_Review_of_its_Traditional_Uses_Phytochemistry_Pharmacology_and_Toxicity
15. Vajradanti Plant: Barleria Prionitis Medicinal Uses & Benefits | Dabur, accessed on August 4, 2025, <https://www.dabur.com/ayurveda/ayurvedic-medicinal-plants/vajradanti-plant>
16. WORLD JOURNAL OF PHARMACEUTICAL RESEARCH - AWS, accessed on August 4, 2025, https://wjpr.s3.ap-south-1.amazonaws.com/article_issue/22c24a1d41834b36058c2490c215d466.pdf
17. International Journal of Ayurveda and Pharma Research, accessed on August 4, 2025, <https://ijapr.in/index.php/ijapr/article/download/3565/3343/>
18. a review of bhavaprakasha: an important ayurvedic treatise - International Journal of Research in Ayurveda and Pharmacy, accessed on August 4, 2025, https://ijrap.net/admin/php/uploads/2994_pdf.pdf
19. zTherapeutic Potential of Kantaka Panchamula in the ... - JETIR.org, accessed on August 4, 2025, <https://www.jetir.org/papers/JETIR2408661.pdf>
20. Barleria prionitis Linn.: a review of its traditional uses, phytochemistry, pharmacology and toxicity., accessed on August 4, 2025, <https://www.cabidigitallibrary.org/doi/full/10.5555/20123187947>
21. WORLD JOURNAL OF PHARMACEUTICAL RESEARCH, accessed on August 4, 2025, https://www.wisdomlib.org/uploads/journals/wjpr/volume-12,-june-special-issue-10_22453.pdf
22. (PDF) A Review: Traditional, Ethnomedicinal Utilization ..., accessed on August 4, 2025, https://www.researchgate.net/publication/317933881_A_Review_Traditional_Ethnomedicinal_Utilization_Pharmacological_Properties_and_Phytochemistry_of_Barleria_prionitis_Linn
23. Ethnobotanical Plant Barleria prionitis, accessed on August 4, 2025, <https://phytochem.nal.usda.gov/ethnobotanical-plant-barleria-prionitis>

24. National Innovation Foundation-India, accessed on August 4, 2025, <https://innovation.nif.org.in/innovation/detail/herbal-treatment-for-skin-disease/28688>
25. Pharmacognosy, Phytochemistry and Traditional Uses ... - bepls, accessed on August 4, 2025, https://bepls.com/march_2020/24.pdf
26. Saireyak (Barleria prionitis) - uses, dosage, home remedies, accessed on August 4, 2025, <https://www.nakraayurveda.com/saireyak-barleria-prionitis/>
27. Pharmacognostical and Pharmacological Profile of Barleria prionitis ..., accessed on August 4, 2025, <https://rjpponline.org/HTMLPaper.aspx?Journal=Research%20Journal%20of%20Pharmacognosy%20and%20Phytochemistry;PID=2011-3-3-3>
28. Barleria prionitis Linn.: A Review of its Traditional Uses ..., accessed on August 4, 2025, <https://scialert.net/abstract/?doi=rjphyto.2012.31.41>
29. Anti-inflammatory activity of 'TAF' an active fraction from the plant ..., accessed on August 4, 2025, <https://pubmed.ncbi.nlm.nih.gov/12639739/>
30. Barleria prionitis L. extracts ameliorate doxorubicin-induced acute ..., accessed on August 4, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC10491988/>
31. Barleria prionitis L. extracts ameliorate doxorubicin-induced acute ..., accessed on August 4, 2025, <https://pubmed.ncbi.nlm.nih.gov/37693098/>
32. Pharmacognostic and Physico-chemical Investigation of Barleria cristata Linn. (Leaf) for Quality Control Assessment, accessed on August 4, 2025, https://pbr.mazums.ac.ir/browse.php?a_id=358&sid=1&slc_lang=en&html=1
33. Phytochemical Screening and Standardization of Extracts from ..., accessed on August 4, 2025, <https://www.ijpsjournal.com/article/Phytochemical+Screening+and+Standardization+of+Extracts+from+Barleria+Prionitis+Leaves>
34. Hemodynamic effects of Sarvanga Swedana (Ayurvedic passive heat therapy): A pilot observational study - PMC - PubMed Central, accessed on August 4, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC3821243/>
35. Sarvanga Parisheka - Utpala Ayurdhama, accessed on August 4, 2025, <https://utpalaayurdhama.com/treatment/sarvanga-parisheka/>